LAST UPDATED
December 03, 2024
Clinicaltrials.gov ID
OVERVIEW
A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A and/or P-glycoprotein (P-gp) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART)
PROTOCOL SUMMARY
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on the study drug, vesatolimod (VES), in people with HIV-1 on antiretroviral therapy (ART).
View moreParticipation requirements
Age
18 years +
Sex
All
Healthy Volunteers
No
Age
18 years +
Sex
All
Healthy Volunteers
No
Study details
Medical Condition
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Gender
N/A
Date
August 2022 - May 2023
Study Type
Interventional
Study Phase
Phase 1
Product
Vesatolimod, Cobicistat, Voriconazole, Rifabutin
Eligibility information
Inclusion criteria
- On an antiretroviral therapy (ART) regimen for at least 6 consecutive months, with no change in the ART regimen within 2 months prior to screening. Permitted ARTs are as follows:
- Cohort 1: A regimen of (bictegravir [BIC], dolutegravir [DTG], raltegravir [RAL], or doravirine [DOR]) plus Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Examples of acceptable regimens include BIC/emtricitabine/tenofovir, DTG/ abacavir (ABC)/3TC, DTG/3TC, DTG + emtricitabine/tenofovir, or DOR/3TC/tenofovir
- Cohort 2: A DTG-based regimen is required (DTG/ABC/3TC), (DTG/3TC), or (DTG + NRTIs)
- Plasma HIV-1 RNA levels less than 50 copies/mL at screening
- Have normal hematologic function with an absolute neutrophil count greater than or equal to 1.5 × 10^9/L, platelets greater than or equal to 150 × 10^9/L; hemoglobin greater than or equal to 10.5 g/dL for females and greater than or equal to 11.5 g/dL for males
- Clusters of differentiation (CD) 4 T cell count greater than or equal to 350 cells/μL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x upper limit of normal (ULN) and total bilirubin less than or equal to 1.5 mg/dL, or normal direct bilirubin and creatinine less than or equal to 1.25 x ULN
- Have a calculated creatinine clearance (CLcr) of at least 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at screening and upon admission
- Individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception
- Must be willing and able to comply with all study requirements and available to complete the study schedule of assessments
- In the judgment of the investigator, be in good general health, based on review of the results from a screening visit
Exclusion criteria
- Have received any study drug within 30 days prior to study dosing
- Participation in any other clinical study (including observation studies) without prior approval from the sponsor is prohibited while participating in this study
- Have current alcohol or substance abuse judged by the investigator to potentially interfere with individual compliance or individual safety, or a positive drug or alcohol test at screening or baseline
- No Evidence of chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] and/or positive HBV core antibody with positive reflex HBV DNA polymerase chain reaction (PCR)). Note: positive HBV core antibody with negative reflex HBV DNA PCR results are acceptable
- No Evidence of active hepatitis C virus (HCV) infection (defined as positive hepatitis C antibody and HCV RNA above lower limit of quantitation). Note: positive anti-HCV antibody and negative HCV PCR results are acceptable
- Acute febrile illness within 35 days prior to Day 1
- Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study
- Received any vaccine or immunomodulatory medication within 4 weeks prior to screening. Elective vaccination (eg, flu shot, hepatitis A or B vaccine) during the course of the study will require prior approval from the sponsor
- Coronavirus disease of 2019 (COVID-19) vaccinations are allowed, with the requirement that they should not be administered within 7 ± 2 days of receiving VES
- Have a history of any of the following:
- Significant serious skin disease, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria
- Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)
- Known hypersensitivity to the study drugs, their metabolites, or to formulation excipients
- Autoimmune disease
- Significant cardiac disease or a family history of long QT syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years
- Syncope, palpitations, or unexplained dizziness
- Implanted defibrillator or pacemaker
- Liver disease, including Gilbert syndrome
- Severe peptic ulcer disease requiring prolonged (≥ 6 months) medical treatment
- Medical or surgical treatment that permanently altered gastric absorption (eg, gastric or intestinal surgery). A history of cholecystectomy is not exclusionary
- Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol
- For Cohort 1, individuals with CYP2C19 genotype of CYP2C19*2/*2, CYP2C19*2/*3, or CYP2C19*3/*3
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Locations
Locations (5)
Collaborative Neuroscience Research, LLC.
Long Beach, California, United States, 90806
Clinical Pharmacology of Miami, LLC.
Miami, Florida, United States, 33014
Triple O Research Institute, P.A.
West Palm Beach, Florida, United States, 33407
Join Gilead Trial Connect and help advance clinical research. Your participation is key to developing future treatments.
Share Trial